Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. provides an overview of its ChemPass AI platform, which uses generative AI to design and optimize novel small molecules for pharmaceutical and agricultural applications. The system combines three tools—PointHit, ActiveSearch and LeadOpGPT—to screen ultra-large libraries and fine‑tune candidates across potency, selectivity, solubility and other properties.
The presentation highlights collaborations with Google Cloud to build a generative AI model trained on 38 billion molecular structures and to integrate AI agents that automate design–make–test–analyze cycles. Evogene outlines a pharma pipeline spanning oncology, immunology, neurology and metabolic disease projects, including programs in aggressive breast cancer and gout‑related metabolic conditions.
In agriculture, work is conducted through its AgPlenus subsidiary, targeting new herbicides and fungicides such as a wheat blotch program in a European fungicide market exceeding $1.2 billion annually. The company emphasizes co‑development and out‑licensing business models with academic groups, biotech firms and global crop protection companies.
Evogene Ltd. is offering up to $2,926,500 of its ordinary shares in an at-the-market (ATM) program under a Sales Agreement with A.G.P./Alliance Global Partners dated June 11, 2026. Sales may occur from time to time on Nasdaq or otherwise at prevailing market prices, with A.G.P. paid a 3.0% commission.
The prospectus supplement states the company’s public float was approximately $8,779,546 (based on $0.85 per share and 10,328,878 shares held by non-affiliates). The offering table shows 12,104,457 ordinary shares outstanding prior to the offering as of June 3, 2026 and illustrates an illustrative post-offering outstanding count of up to 17,006,467 shares assuming sale of 4,902,010 shares at $0.597 per share (the last reported sale on June 9, 2026).
Evogene Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners for an at-the-market equity program allowing sales of its ordinary shares for an aggregate offering price of up to $2,926,500 under an effective Form F-3 shelf registration.
The agent may sell shares on Nasdaq, in block trades, or in privately negotiated transactions, using commercially reasonable efforts based on Evogene’s instructions. Evogene will pay a 3.0% cash commission on gross proceeds, is not obligated to sell any shares, and either party may terminate the agreement as provided. A legal opinion from Meitar | Law Offices and the Sales Agreement are filed as exhibits.
Evogene Ltd. registers 2,446,707 ordinary shares for resale by a selling shareholder via Prospectus Supplement No. 1. This supplement adds the company's GAAP Q1 2026 financial statements and updates the prospectus dated March 26, 2026.
The consolidated balance sheet shows $8.5M cash and cash equivalents as of March 31, 2026 and 10,412,764 ordinary shares issued and outstanding as of March 31, 2026. The three‑month loss was $(5,896) thousand. The resale is by a selling shareholder; issuer proceeds are not received from these resales.
Evogene Ltd. reported a weak first quarter of 2026 as it invests heavily in its AI-driven small-molecule platforms while revenue fell sharply. Revenue from continuing operations was $334 thousand for the quarter ended March 31, 2026, compared with $2.343 million in the same period of 2025, leading to a gross profit of $204 thousand.
The company recorded an operating loss of $3.15 million and a net loss of $5.9 million, versus a $2.99 million loss a year earlier, reflecting higher financing expenses tied in part to warrant-related items. Cash and cash equivalents declined to $8.5 million from $12.96 million at year-end 2025, as operating and investing activities used cash despite financing inflows from a warrant inducement share issuance. Strategically, Evogene expanded its pharma activity with three new collaborations, continued progress in its AgPlenus herbicide and fungicide programs, and entered a second AI collaboration with Google Cloud, while a herbicide project with Bayer was discontinued and its assets reverted to AgPlenus.
Evogene Ltd. reports that its subsidiary Ag Plenus Ltd. (AgPlenus) and Bayer AG have decided to discontinue their joint herbicide development project, effective May 18, 2026, after determining the target protein did not meet required product criteria.
All assets previously licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus. The report is also incorporated by reference into Evogene’s effective Form F-3 and multiple Form S-8 registration statements.
EVOGENE LTD. Schedule 13G reports that Armistice Capital, LLC and Steven Boyd beneficially own 1,104,906 ordinary shares, representing 9.99% of the class as reported. The filing states Armistice Capital exercises shared voting and dispositive power over these shares pursuant to an Investment Management Agreement. The filing is dated 05/15/2026 and cites a position as of 03/31/2026.
Evogene Ltd. executive Ravzin Polina, VP Finance, reported existing holdings of stock options on a Form 3. These options cover a total of 20,000 underlying ordinary shares with exercise prices ranging from 0.945 to 12.210 and expiration dates between 2032 and 2036, reflecting previously granted equity compensation that vests quarterly over four years for recent grants.